Dr Javier Cortés speaks to ecancer about the results of the randomised phase 3 DESTINY-Breast03 study. Initially, he explains the rationale and design of the study.
This study investigated trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer. He says that T-DXd demonstrated a highly statistically significant and clinically meaningful improvement in PFS vs T-DM1 in patients previously treated with trastuzumab and taxane for HER2+ mBC.
These data confirm that T-DXd is tolerable with manageable toxicity and a significant improvement in ILD profile vs studies performed in more heavily pretreated patients.
Dr Cortés concludes by discussing the impact these results can have on the future treatment of breast cancer.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.